Business Wire · BCG · October 14, 2026

FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

Get the app for more

Explore stock news, insights and company research.